With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

Dimensional Fund Advisors LP boosted its stake in Regeneron Pharmaceuticals by 3% in Q4, totaling over $418 million in ...

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced a major expansion of its manufacturing capacity, including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Biocon Biologics Ltd, announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept, ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...